Results 1 to 10 of about 13,121 (228)

Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD [PDF]

International Journal of COPD, 2018
Anthony D D’Urzo,1 Peter Kardos,2 Russell Wiseman3 1Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, ON, Canada; 2Group Practice and Centre for Allergy, Respiratory and Sleep Medicine, Red Cross Maingau ...
D’Urzo AD, Kardos P, Wiseman R
doaj   +10 more sources

Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit

International Journal of COPD, 2012
Charlotte Suppli UlrikDepartment of Pulmonary Medicine, Hvidovre Hospital and University of Copenhagen, Copenhagen, DenmarkBackground: Long-acting bronchodilators are central in the pharmacological management of patients with chronic obstructive ...
Ulrik CS
doaj   +5 more sources

Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan [PDF]

Frontiers in Physiology, 2023
Background: The Japanese drug use system allowed the once-daily use of inhaled corticosteroid fluticasone furoate (FF) combined with a long-acting beta-2 agonist vilanterol (VI) and a long-acting muscarinic antagonist umeclidinium (UMEC) against asthma ...
Akira Umeda, Akira Umeda, Hisato Shimada, Tateki Yamane, Taichi Mochizuki, Yasushi Inoue, Kenji Tsushima, Kazuya Miyagawa, Atsumi Mochida, Hiroshi Takeda, Yasumasa Okada, Katsunori Masaki, Masako Matsusaka, Koichi Fukunaga   +13 more
doaj   +4 more sources

Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis [PDF]

International Journal of COPD, 2015
Afisi Segun Ismaila,1,2 Eline L Huisman,3 Yogesh Suresh Punekar,4 Andreas Karabis31Value Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC, USA; 2Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; 3Real ...
Ismaila AS, Huisman EL, Punekar YS, Karabis A   +3 more
doaj   +3 more sources

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease

Journal of Experimental Pharmacology, 2020
Josuel Ora,1 Angelo Coppola,2 Mario Cazzola,3 Luigino Calzetta,4 Paola Rogliani1,3 1Division of Respiratory Medicine, University Hospital Tor Vergata, Rome, Italy; 2Division of Respiratory Medicine, San Filippo Neri Hospital, Rome, Italy; 3Department of ...
Ora J, Coppola A, Cazzola M, Calzetta L, Rogliani P   +4 more
doaj   +2 more sources

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis [PDF]

BMC Pulmonary Medicine, 2020
Background Revefenacin, a once-daily, long-acting muscarinic antagonist delivered via standard jet nebulizer, increased trough forced expiratory volume in 1 s (FEV1) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in
James F. Donohue, Edward Kerwin, Chris N. Barnes, Edmund J. Moran, Brett Haumann, Glenn D. Crater   +5 more
doaj   +2 more sources

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD [PDF]

Scientific Reports, 2023
Few studies have directly compared the incidence of pneumonia in patients on common chronic obstructive pulmonary disease (COPD) treatments such as long-acting muscarinic antagonists (LAMA) with those on inhaled corticosteroids and long-acting β2-agonist
Eung Gu Lee, Youlim Kim, Yong Il Hwang, Kwang Ha Yoo, So Eun Lee, Kyung Yoon Jung, Doik Lee, Yong Bum Park, Chin Kook Rhee   +8 more
doaj   +2 more sources

NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease

Therapeutic Advances in Respiratory Disease, 2011
Bronchodilation with a long-acting muscarinic antagonist (LAMA) or long-acting β 2 -agonist is central to the management of chronic obstructive pulmonary disease (COPD).
Claus F Vogelmeier, Donald Banerji
exaly   +3 more sources

Tiotropium bromide, a long acting muscarinic receptor antagonist triggers intracellular calcium signalling in the heart [PDF]

Toxicology and Applied Pharmacology, 2019
Background and purpose: Tiotropium bromide (TB) is a long acting muscarinic receptor antagonist used to manage chronic obstructive pulmonary disease (COPD). Recent meta-analyses suggest an increased risk of cardiovascular events with TB.
Shabana Cassambai, Derek Renshaw, Afthab Hussain   +2 more
exaly   +2 more sources

Long-acting muscarinic antagonist and long-acting β₂-agonist combination for the treatment of maintenance therapy-naïve patients with chronic obstructive pulmonary disease: a narrative review. [PDF]

Ther Adv Respir Dis
Chronic obstructive pulmonary disease; Long-acting muscarinic antagonist; Long-acting beta-adrenoceptor agonistMalaltia pulmonar obstructiva crònica; Antagonista muscarínic d'acció prolongada; Agonista beta2 d'acció perllongadaEnfermedad pulmonar ...
Buhl R, Miravitlles M, Anzueto A, Brunton S.   +3 more
europepmc   +2 more sources